NCT06939283View on ClinicalTrials.gov

A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Advanced or Metastatic Solid TumorsNon-Hodgkin Lymphoma
Interventions
DRUG

WTX-330

Investigational Product

Trial Locations (5)

30322

RECRUITING

Emory Winship Cancer Institute, Atlanta

46202

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

60611

RECRUITING

Northwestern University, Chicago

78229

RECRUITING

NEXT Oncology, San Antonio

85258

RECRUITING

HonorHealth Research Institute, Scottsdale

All Listed Sponsors
lead

Werewolf Therapeutics, Inc.

INDUSTRY